XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Offsetting (Tables)
 9 Months Ended
Sep. 30, 2021
Offsetting [Abstract]  
Offsetting Assets
The table below presents information about Valley’s financial instruments eligible for offset in the consolidated statements of financial condition as of September 30, 2021 and December 31, 2020.
    Gross Amounts Not Offset 
 Gross Amounts
Recognized		Gross Amounts
Offset		Net Amounts
Presented		Financial
Instruments
Cash
Collateral (1)
Net
Amount
 (in thousands)
September 30, 2021
Assets:
Interest rate swaps$215,046 $— $215,046 $— $— $215,046 
Liabilities:
Interest rate swaps $65,212 $— $65,212 $— $(60,177)$5,035 
Total$65,212 $— $65,212 $— $(60,177)$5,035 
December 31, 2020
Assets:
Interest rate swaps$150,487 $— $150,487 $— $— $150,487 
Liabilities:
Interest rate swaps$150,487 $— $150,487 $— $(150,487)$— 
Repurchase agreements300,000 — 300,000 (300,000)
(2)
— — 
Total$450,487 $— $450,487 $(300,000)$(150,487)$— 
(1)    Cash collateral pledged to our counterparties in relation to market value exposures of OTC derivative contacts in a liability position.
(2)    Represents the fair value of non-cash pledged investment securities.
Offsetting Liabilities
The table below presents information about Valley’s financial instruments eligible for offset in the consolidated statements of financial condition as of September 30, 2021 and December 31, 2020.
    Gross Amounts Not Offset 
 Gross Amounts
Recognized		Gross Amounts
Offset		Net Amounts
Presented		Financial
Instruments
Cash
Collateral (1)
Net
Amount
 (in thousands)
September 30, 2021
Assets:
Interest rate swaps$215,046 $— $215,046 $— $— $215,046 
Liabilities:
Interest rate swaps $65,212 $— $65,212 $— $(60,177)$5,035 
Total$65,212 $— $65,212 $— $(60,177)$5,035 
December 31, 2020
Assets:
Interest rate swaps$150,487 $— $150,487 $— $— $150,487 
Liabilities:
Interest rate swaps$150,487 $— $150,487 $— $(150,487)$— 
Repurchase agreements300,000 — 300,000 (300,000)
(2)
— — 
Total$450,487 $— $450,487 $(300,000)$(150,487)$— 
(1)    Cash collateral pledged to our counterparties in relation to market value exposures of OTC derivative contacts in a liability position.
(2)    Represents the fair value of non-cash pledged investment securities.